FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Mithra Pharmaceuticals S.A. Stock AnalysisComprehensive stock analysis for Mithra Pharmaceuticals S.A. (MITPF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMITPF
MITPF
Mithra Pharmaceuticals S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MITPF
Home🔹Stocks🔹Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITPF•OTC

Mithra Pharmaceuticals S.A.

MITPF•OTC
Market cap
$1.60B
Sentiment

Your view on MITPF

Mkt Cap
$1.60B
Sentiment
Your view
MITPF
Mithra Pharmaceuticals S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
MITPF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Mithra Pharmaceuticals S.A.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christophe Marechal
Headquarters
Rue Saint-Georges 5, Liège, BE
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Christophe Marechal
Headquarters
Rue Saint-Georges 5, Liège, BE
Description

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News